What is it about?
Recent innovative non-pharmacological interventions and neurostimulation devices have shown potential for application in the treatment of Alzheimer’s disease. These include photobiomodulation therapy. This randomized control trial assesses a brain-gut photobiomodulation therapy for Alzheimer’s disease patients.
Featured Image
Photo by Natasha Connell on Unsplash
Why is it important?
This is the first randomized controlled trial in Alzheimer's disease evaluating the first medical device that targets the brain-gut axis. The brain-gut photobiomodulation therapy proved to be safe. The majority of the patients were highly compliant. Despite its reduced statistical power due in part to the premature study termination related to the COVID-19 pandemic, this study also highlights encouraging efficacy trends on certain outcomes.
Perspectives
The present study provides valuable insights for the design of the next phase trial, which will address the cognitive benefits of the brain-gut photobiomodulation therapy in a larger sample of Alzheimer’s disease patients. This pivotal trial could demonstrate that REGEnLIFE’s brain-gut photobiomodulation device could be a safe, well-tolerated and efficient treatment for mild-to-moderate Alzheimer’s disease patients, with medical and economic benefits.
Guillaume Blivet
REGENLIFE
Read the Original
This page is a summary of: A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance, Journal of Alzheimer s Disease, November 2022, IOS Press,
DOI: 10.3233/jad-220467.
You can read the full text:
Resources
Neuroprotective effect of a new photobiomodulation technique against Aβ25-35 peptide-induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested
Photobiomodulation was assessed as a novel treatment of Alzheimer's disease (AD) by the use of a new device RGn500 combining photonic and magnetic emissions in a mouse model of AD. Following the injection of amyloid β 25-35 peptide in male Swiss mice, RGn500 was applied once a day for 7 days either on the top of the head or the center of abdomen or both. RGn500 daily application for 10 min produced a neuroprotective effect on the neurotoxic effects of amyloid β 25-35 peptide injection when this type of photobiomodulation was applied both on the head and on the abdomen. Protection was demonstrated by memory restoration and on the normalization of key markers of AD (amyloid β 1-42, pTau), oxidative stress (lipid peroxidation), apoptosis (Bax/Bcl2) and neuroinflammation. RGn500 displays therapeutic efficacy similar to other pharmacological approaches evaluated in this model of AD.
REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease
Montpellier, France, March 17, 2021 – REGEnLIFE, a company specialized in the research and development of innovative photo-medical technologies for the prevention and treatment of neurodegenerative diseases, announces today the promising results of the pilot clinical trial evaluating its technology in Alzheimer’s disease (AD). The results were presented by Professor Jacques Touchon, scientific advisor on the trial, at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2021), held online from March 9 to 14, 2021.
Contributors
The following have contributed to this page
